Neovacs S.A.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IF… Read more
Neovacs S.A. (ALNEV) - Total Liabilities
Latest total liabilities as of June 2025: €4.18 Million EUR
Based on the latest financial reports, Neovacs S.A. (ALNEV) has total liabilities worth €4.18 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Neovacs S.A. - Total Liabilities Trend (2007–2024)
This chart illustrates how Neovacs S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Neovacs S.A. Competitors by Total Liabilities
The table below lists competitors of Neovacs S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
World Chess PLC
LSE:CHSS
|
UK | GBX2.97 Million |
|
Thunderbird Minerals Corp.
V:BIRD
|
Canada | CA$217.97K |
|
Restart Life Sciences Corp.
PINK:NMLSD
|
USA | $214.89K |
|
Reem Capital Corp.
V:REEM-P
|
Canada | CA$82.37K |
|
Theracryf Plc
LSE:TCF
|
UK | GBX1.82 Million |
|
CANADA ZINC METALS
MU:M9R
|
Germany | €1.47 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Neovacs S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neovacs S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neovacs S.A. (2007–2024)
The table below shows the annual total liabilities of Neovacs S.A. from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €4.01 Million | +7.98% |
| 2023-12-31 | €3.71 Million | -26.53% |
| 2022-12-31 | €5.05 Million | +8.62% |
| 2021-12-31 | €4.65 Million | +85.71% |
| 2020-12-31 | €2.50 Million | -47.81% |
| 2019-12-31 | €4.80 Million | -0.06% |
| 2018-12-31 | €4.80 Million | -55.64% |
| 2017-12-31 | €10.82 Million | +33.98% |
| 2016-12-31 | €8.08 Million | +55.84% |
| 2015-12-31 | €5.18 Million | +48.65% |
| 2014-12-31 | €3.49 Million | -16.75% |
| 2013-12-31 | €4.19 Million | +61.63% |
| 2012-12-31 | €2.59 Million | +7.37% |
| 2011-12-31 | €2.41 Million | +0.39% |
| 2010-12-31 | €2.40 Million | -50.70% |
| 2009-12-31 | €4.88 Million | +122.67% |
| 2008-12-31 | €2.19 Million | +7.61% |
| 2007-12-31 | €2.04 Million | -- |